Dossier
immunology sales
Coverage of immunology sales in the Nexus archive.
- AbbVie beat profit estimates but cut its forecast — and the stock sank
AbbVie exceeded second-quarter profit estimates due to strong immunology sales but reduced its full-year adjusted earnings outlook, leading to a stock price decline.